Latest Breaking News On - Paul clozel - Page 18 : comparemela.com

Idorsia Pharmaceuticals Ltd: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Ad hoc announcement pursuant to Art. 53 LR Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study Idorsia

Switzerland generalUnited kingdomAndrewc weissJean paul clozelIdorsia ltdHead of investor relations corporate communicationsIdorsia pharmaceuticals ltdSwiss exchangePaul clozelChief executive officerMol genetVice presidentInvestor relationsPharmaceuticals ltd

Press Release: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Press Release: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study Ad hoc announcement pursuant to Art.

United kingdomJean paul clozelIdorsia ltdPress releasePaul clozelChief executive officerDow jones newswires

Idorsia Pharmaceuticals Ltd: Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus

Ad hoc announcement pursuant to Art. 53 LR Cenerimod 4 mg showed clinically meaningful improvement in the mSLEDAI-2K primary efficacy endpoint and other measures of efficacy, consistent with the effect

Switzerland generalUnited statesMartine clozelAndrewc weissGuy braunsteinJean paul clozelIdorsia ltdHead of investor relations corporate communicationsHead of global clinical development idorsiaIdorsia pharmaceuticals ltdSwiss exchangeSystemic lupus erythematosus disease activitySystemic lupus erythematosus responder indexGlobal clinical developmentChief scientific officerPaul clozel

GNW: Idorsia to advance cenerimod into Phase 3 development for treatment of | Newsticker

GNW: Idorsia to advance cenerimod into Phase 3 development for treatment of | Newsticker
fuw.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fuw.ch Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalMartine clozelGuy braunsteinJean paul clozelIdorsia ltdHead of global clinical development idorsiaSystemic lupus erythematosus disease activitySystemic lupus erythematosus responder indexGlobal clinical developmentChief scientific officerPaul clozelChief executive officer

Idorsia Pharmaceuticals Ltd: Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - October 11, 2021Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as

Switzerland generalAndrewc weissGuy braunsteinJean paul clozelDevelopmentat idorsiaIdorsia ltdHead of investor relations corporate communicationsIdorsia pharmaceuticals ltdSwiss exchangeGlobal clinical developmentat idorsiaPaul clozelChief executive officerVice presidentInvestor relationsPharmaceuticals ltd